Evidence map›Paper›PMID 34754397›Full record

ReviewWorld journal of cardiology2021

Lipid lowering in patients 75 years and older.

Umidakhon Makhmudova, P Christian Schulze, Harry R Davis, Oliver Weingärtner

Abstract readReview
In one paragraph

Review in World journal of cardiology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Umidakhon MakhmudovaKlinik für Innere Medizin I, Universitätsklinikum Jena, Jena 07747, Germany.
P Christian SchulzeKlinik für Innere Medizin I, Universitätsklinikum Jena, Jena 07747, Germany.
Harry R DavisSynergy Partners RD Solutions, Synergy Partners RD Solutions, Gaithersburg, MD 20850, United States.
Oliver WeingärtnerKlinik für Innere Medizin I, Universitätsklinikum Jena, Jena 07747, Germany. oliver.weingaertner@med.uni-jena.de.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

More than twenty years ago, knowledge about the importance of cholesterol absorption and the potential therapeutic effect of its inhibition led to the discovery and clinical application of the first and only cholesterol absorption inhibitor to date - ezetimibe. Since then, ezetimibe has become a well-recognized player in lipid-lowering therapy. Recent findings of IMPROVE-IT and EWTOPIA 75 imply that elderly patients over the age of 75 years in particular benefit from ezetimibe. This review summarizes the evidence, discusses the possible underlying pathophysiological mechanisms and calls for a change in future dyslipidemia guidelines.

Indexed as

CholesterolCholesterol absorptionCholesterol synthesisElderlyEzetimibe

Identifiers

PMID34754397
PMCPMC8554361

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.